3 New Strong Buy Ratings from Top-Rated Analysts: 01/13/2026

All of these stocks have excellent Zen Ratings and strong analyst support:

• Enhabit (EHAB) benefits from increased hospice demand 
• Anaptysbio Inc (ANAB) hits a major catalyst 
• HF Sinclair (DINO) sharpens its earnings profile 

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Enhabit (NYSE: EHAB)

Enhabit Inc is emerging as a healthcare standout — ranking #3 in its industry and benefiting from powerful demand tailwinds in home health and hospice care.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $10.05 — get current quote

Max 1-year forecast: $12.00

Why we're watching:

• Analyst support: Admittedly, EHAB only has one rating right now among the analysts we track — but it’s a bullish Strong Buy, with a price target that suggests over 20% potential upside. See the ratings
• The company is currently experiencing increasing market demand for medical care facilities, with strategic initiatives expected to enhance profitability and operational efficiencies throughout 2026.
• Industry ranking context: EHAB is currently the 3rd highest-rated stock out of 42 in the Medical Care Facility industry, which has an Industry Rating of A.
• With its Zen Rating of A (Strong Buy), EHAB is in a class of stocks that have historically delivered 32.52% annual returns — a testament to its growth potential in the expanding home healthcare market.
• Component Grades: EHAB has an exceptional Growth (A) grade combined with strong Safety (B) and Financials (B) scores, which demonstrate the company's balanced risk-reward profile.  See all 7 Zen Component Grades here

2. Anaptysbio (NASDAQ: ANAB)

AnaptysBio just hit a major catalyst, submitting an FDA Biologics License Application for a leading drug in Generalized Pustular Psoriasis.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $45.00 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: 9 analysts we track cover the stock. It currently has 6 Strong Buy, 2 Buy, and 1 Hold ratings, demonstrating strong buy-side conviction. See the ratings
• UBS researcher Michael Yee (a top 19% rated analyst) recently assumed coverage with a Strong Buy rating and $70.00 price target (+56.70% upside), highlighting improving biotech fundamentals and anticipating a successful 2026 as investor confidence rebounds.
• Barclays' Etzer Darout (top 4%) maintains Strong Buy at $55.00, while Guggenheim's Yatin Suneja (top 4%) also rates it Strong Buy, reflecting consensus among top-tier analysts.
• Industry ranking context: While ANAB ranks an impressive 13 out of 490 stocks in the Biotech industry, it’s worth noting that the industry has a dismal F rating. Find out more about Industry Ratings here. 
• Zen Rating highlights: As an A (Strong Buy) rated stock in the Zen Ratings, ANAB shows exceptional attributes based on our 115-factor review, which suggests near-term success for the stock. 
• Component Grades: Strong Value (B), Growth (B), Momentum (B), and exceptional Sentiment (A) grades showcase both fundamental strength and positive market perception around ANAB. See all 7 Zen Component Grades here

3. HF Sinclair (NYSE: DINO)

HF Sinclair Corporation is sharpening its earnings profile by cutting 2026 capex while expanding higher-margin lubricants and specialty products through smart acquisitions.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $50.33 — get current quote

Max 1-year forecast: $68.00

Why we're watching:

• Analyst support: 9 analysts covering the stock with 5 Strong Buy, 2 Buy, and 2 Hold ratings, reflecting strong conviction across Wall Street. See the ratings
• Piper Sandler researcher Ryan Todd (a top 11% rated analyst) recently upgraded to Strong Buy with a $68.00 price target, representing +35.19% upside potential.
• Mizuho's Nitin Kumar (top 5%) maintains a Buy rating at $63.00, while Raymond James' Justin Jenkins (top 1%) reiterates Strong Buy at $65.00, highlighting broad-based analyst enthusiasm.
• Industry ranking context: DINO is currently the 3rd highest-rated stock in the Oil & Gas Refining & Marketing industry, which has an Industry Rating of A.
• Zen Rating highlights: A (Strong Buy) stocks average +32.52%/yr — ranks in top 15% of tracked stocks with strong earnings growth prospects of +147.63% next year.
• Component Grades: Strong Value (top 20%), Growth (top 15%), and Financials (top 35%) percentiles reflect DINO's attractive valuation at 23.62x P/E combined with 18.11% ROE and solid cash generation. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.